New drug cizutamig tested for tough ulcerative colitis cases

NCT ID NCT07353450

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test a new drug called cizutamig in 15 people with moderate to severe ulcerative colitis who haven't improved with other treatments. The main goal is to check if the drug is safe and tolerable. It is not yet recruiting and will be conducted at a single center in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cizutamig
What this could lead to
If it works, this could point toward a new treatment option for people with moderate to severe ulcerative colitis who haven't responded to other therapies.
What could go wrong
This is a very early, small trial (15 people) focused on safety, not effectiveness. It may not lead to a proven treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.